<!DOCTYPE html SYSTEM "about:legacy-compat"><html lang="en-US" data-colors-preset="contrast" data-primary-color="#307FFF"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="UTF-8">  <meta name="built-on" content="2024-01-01T13:06:23.6105974"><meta name="build-number" content="${buildNumber}">       <title>中信建投：GLP-1类药物有望在NASH和AD等适应症中迎来突破 提升靶点及产业价值 | 2023-10-17</title><script id="virtual-toc-data" type="application/json">[]</script><script id="topic-shortcuts" type="application/json"></script><link href="https://resources.jetbrains.com/writerside/apidoc/6.6.6-b205/app.css" rel="stylesheet">   <link rel="apple-touch-icon" sizes="180x180" href="https://jetbrains.com/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="https://jetbrains.com/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="https://jetbrains.com/favicon-16x16.png"><link rel="manifest" href="https://jetbrains.com/site.webmanifest"><link rel="mask-icon" href="https://jetbrains.com/safari-pinned-tab.svg" color="#000000"><meta name="msapplication-TileColor" content="#000000"/><meta name="msapplication-TileImage" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-144x144.png"/><meta name="msapplication-square70x70logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-70x70.png"/><meta name="msapplication-square150x150logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-150x150.png"/><meta name="msapplication-wide310x150logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-310x150.png"/><meta name="msapplication-square310x310logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-310x310.png"/>  <meta name="image" content=""><!-- Open Graph --><meta property="og:title" content="中信建投：GLP-1类药物有望在NASH和AD等适应症中迎来突破 提升靶点及产业价值 | 2023-10-17"/><meta property="og:description" content=""/><meta property="og:image" content=""/><meta property="og:site_name" content="2023-10-17 Help"/><meta property="og:type" content="website"/><meta property="og:locale" content="en_US"/><meta property="og:url" content="3903.html"/><!-- End Open Graph --><!-- Twitter Card --><meta name="twitter:card" content="summary_large_image"><meta name="twitter:site" content=""><meta name="twitter:title" content="中信建投：GLP-1类药物有望在NASH和AD等适应症中迎来突破 提升靶点及产业价值 | 2023-10-17"><meta name="twitter:description" content=""><meta name="twitter:creator" content=""><meta name="twitter:image:src" content=""><!-- End Twitter Card --><!-- Schema.org WebPage --><script type="application/ld+json"> { "@context": "http://schema.org", "@type": "WebPage", "@id": "3903.html#webpage", "url": "3903.html", "name": "中信建投：GLP-1类药物有望在NASH和AD等适应症中迎来突破 提升靶点及产业价值 | 2023-10-17", "description": "", "image": "", "inLanguage":"en-US" }</script><!-- End Schema.org --><!-- Schema.org WebSite --><script type="application/ld+json"> { "@type": "WebSite", "@id": "/#website", "url": "/", "name": "2023-10-17 Help" }</script><!-- End Schema.org --></head>      <body data-id="3903" data-main-title="中信建投：GLP-1类药物有望在NASH和AD等适应症中迎来突破 提升靶点及产业价值" data-article-props="{&quot;seeAlsoStyle&quot;:&quot;links&quot;}"  data-template="article"  data-breadcrumbs=""  >   <div class="wrapper"><main class="panel _main"><header class="panel__header"><div class="container"><h3>2023-10-17  Help</h3><div class="panel-trigger"></div></div></header><section class="panel__content"><div class="container"><article class="article" data-shortcut-switcher="inactive"><h1 data-toc="3903"   id="3903.md">中信建投：GLP-1类药物有望在NASH和AD等适应症中迎来突破 提升靶点及产业价值</h1>  <p id="a1b3f56b_22"><span class="control" id="a1b3f56b_23">2023-10-17 00:23</span></p><p id="a1b3f56b_24"><span class="control" id="a1b3f56b_25">https://api3.cls.cn/share/article/1486899?os=web&amp;sv=7.7.5&amp;app=CailianpressWeb</span></p><p id="a1b3f56b_26">【中信建投：GLP-1类药物有望在NASH和AD等适应症中迎来突破 提升靶点及产业价值】财联社10月17日电，中信建投研报指出，诺和诺德司美格鲁肽在此前CVOT临床试验成功的基础上又再下一城，在慢性肾病FLOW III期临床研究中因达到预期终点而提前终止临床试验，相应用药人群全球超1亿人，市场空间超200亿美元。我们认为，GLP-1类药物目前已在2型糖尿病、超重与肥胖、心脑血管疾病、射血分数保留型心衰和慢性肾病中展现出临床获益，可覆盖人群庞大。未来，GLP-1类药物有望在NASH和AD等适应症中迎来突破，造福更多患者的同时进一步提升靶点及产业价值。</p><div class="last-modified"> Last modified: 01 一月 2024</div><div data-feedback-placeholder="true"></div><div class="navigation-links _bottom">  <a class="navigation-links__prev" href="3904.html">投资日历：周二资本市场大事提醒</a>   <a class="navigation-links__next" href="3902.html">财联社10月17日电，日经225指数开盘涨1.28%；韩国KOSPI指数涨0.73%。</a>  </div></article><div id="disqus_thread"></div></div></section></main></div>  <script src="https://resources.jetbrains.com/writerside/apidoc/6.6.6-b205/app.js"></script></body></html>